Surinabant
Surinabant is a selective antagonist of the CB1 receptor and was researched as a potential treatment for nicotine addiction and obesity. It was developed by Sanofi-Aventis but its development was discontinued in 2011.
History[edit | edit source]
Sanofi-Aventis, a global pharmaceutical company, developed Surinabant with the aim of treating conditions such as nicotine addiction and obesity. The development of Surinabant was part of a wider trend in the pharmaceutical industry to explore the therapeutic potential of cannabinoid receptor antagonists. However, the development of Surinabant was discontinued in 2011.
Pharmacology[edit | edit source]
Surinabant is a selective antagonist of the CB1 receptor, which is one of the two main receptors in the endocannabinoid system. The CB1 receptor is primarily located in the brain and is involved in a variety of physiological processes, including appetite regulation and the addictive properties of nicotine. By blocking the CB1 receptor, Surinabant was intended to reduce appetite and decrease the rewarding effects of nicotine.
Clinical Trials[edit | edit source]
Surinabant underwent several clinical trials to assess its safety and efficacy. However, the results of these trials were mixed. Some studies suggested that Surinabant could reduce the rewarding effects of nicotine and decrease appetite. However, other studies found that Surinabant had little effect on appetite and did not significantly reduce nicotine cravings. In addition, some participants in the trials reported experiencing adverse side effects, including depression and anxiety.
Discontinuation[edit | edit source]
The development of Surinabant was discontinued in 2011. This decision was made in light of the mixed results from the clinical trials and the reported side effects. The discontinuation of Surinabant was part of a wider trend in the pharmaceutical industry, with several other companies also discontinuing their development of CB1 receptor antagonists around the same time.
See Also[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
| This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
